Destiny Health

Destiny Pharma is a clinical-stage biotechnology company dedicated to the development of novel anti-infectives that prevent life-threatening infections and address the global challenge of antimicrobial resistance. The company's lead asset, XF-73, is a first-in-class synthetic dicationic porphyrin formulated as a nasal gel for the prevention of post-surgical staphylococcal infections, which has successfully completed Phase 2b trials. Another core program, NTCD-M3, is a non-toxigenic strain of Clostridioides difficile designed to prevent the recurrence of C. difficile infections by restoring a healthy gut microbiome. Destiny Pharma leverages its proprietary XF platform to create drugs that kill bacteria rapidly without inducing resistance, positioning itself as a leader in infection prevention and microbiome-based therapies.